Announced Date: 2022-12-22 (December 22, 2022)
Asset: Seven investigational preclinical ADC for the treatment of cancer.
Licensor: Kelun-Biotech (subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd, China)
Licensee (Buyer): Merck，known as MSD outside of the United States and Canada,
.
Asset Modality: Antibody drug conjugate (ADC)
Asset Target: Undisclosed
Current Stage: preclinical
Scope of Authority:
Kelun-Biotech has granted Merck exclusive global licenses to research, develop, manufacture and commercialize multiple investigational preclinical ADC therapies and exclusive options to obtain additional licenses to ADC candidates.
Kelun-Biotech retains the right to research, develop, manufacture and commercialize certain licensed and option ADCs for mainland China, Hong Kong and Macau.
.
Deal Detail:
Upfront payment of $175 million,
Milestone payments up to $9.3 billion,
Total up to $9.475 billion.
Merck also intends to make an equity investment in Kelun-Biotech.
.
Link:
Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer
